Ergoteles’s NeoGenomics NEO Stock Holding History

Ergoteles’s Portfolio NEO Stock Details NEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-15,701	Closed	-$536K	–	1504
2021 Q4	$536K	Buy	+15,701	New	+$615K	0.02%	615
2021 Q3	–	Sell	-18,414	Closed	-$832K	–	1529
2021 Q2	$832K	Buy	+18,414	New	+$816K	0.02%	570

Other funds holding NEO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Ergoteles's NEO Position: Q1 2022 in Review

Ergoteles sold out of NeoGenomics (NEO) in Q1 2022, closing a stake of 15,701 shares — an estimated $536K sold.

Ergoteles first reported a position in NEO in Q2 2021 and held it in 2 quarters. The position peaked at $832K in Q2 2021. 279 funds tracked by Wall St. Rank hold NEO as of Q1 2022.

Ergoteles reported no remaining NeoGenomics position as of Q1 2022 after selling out during the quarter.
Ergoteles sold 15,701 NeoGenomics shares in Q1 2022, an estimated $536K.
Ergoteles first reported a position in NeoGenomics in Q2 2021 and held it in 2 quarters.
Ergoteles's NeoGenomics position peaked at $832K in Q2 2021.
279 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2022.

Based on Ergoteles's 13F filing for Q1 2022, filed 13 May 2022.